Oculis updates share capital for its existing at-the-market offering program
Oculis Holding AG (Nasdaq: OCS; XICE: OCS) has issued 2,500,000 new registered ordinary shares with a nominal value of CHF 0.01 each from its existing capital band. These shares are currently recorded as treasury shares. The company's total registered shares now stand at 48,943,700, with approximately 43 million shares outstanding. Following this issuance, treasury shares represent 7.2% of the company's registered shares.
The new shares were issued in connection with an at-the-market (ATM) offering program established through a sales agreement with Leerink Partners on May 8, 2024. Under this program, Oculis may offer and sell ordinary shares worth up to $100 million through Leerink Partners as its sales agent. The newly issued shares have not been sold under the ATM program and are being held in reserve as treasury shares.
Oculis Holding AG (Nasdaq: OCS; XICE: OCS) ha emesso 2.500.000 nuove azioni ordinarie registrate con un valore nominale di CHF 0,01 ciascuna dal suo capitale esistente. Queste azioni sono attualmente registrate come azioni di proprietà. Il totale delle azioni registrate della società ora ammonta a 48.943.700, con circa 43 milioni di azioni in circolazione. Dopo questa emissione, le azioni di proprietà rappresentano il 7,2% delle azioni registrate della società.
Le nuove azioni sono state emesse in relazione a un programma di offerta at-the-market (ATM) stabilito attraverso un accordo di vendita con Leerink Partners l'8 maggio 2024. Sotto questo programma, Oculis può offrire e vendere azioni ordinarie per un valore fino a 100 milioni di dollari tramite Leerink Partners come suo agente di vendita. Le nuove azioni emesse non sono state vendute nell'ambito del programma ATM e sono mantenute in riserva come azioni di proprietà.
Oculis Holding AG (Nasdaq: OCS; XICE: OCS) ha emitido 2,500,000 nuevas acciones ordinarias registradas con un valor nominal de CHF 0.01 cada una de su capital existente. Estas acciones están actualmente registradas como acciones en tesorería. El total de acciones registradas de la compañía ahora asciende a 48,943,700, con aproximadamente 43 millones de acciones en circulación. Tras esta emisión, las acciones en tesorería representan el 7.2% de las acciones registradas de la compañía.
Las nuevas acciones se emitieron en relación con un programa de oferta en el mercado (ATM) establecido a través de un acuerdo de venta con Leerink Partners el 8 de mayo de 2024. Bajo este programa, Oculis puede ofrecer y vender acciones ordinarias por un valor de hasta 100 millones de dólares a través de Leerink Partners como su agente de ventas. Las nuevas acciones emitidas no se han vendido bajo el programa ATM y se mantienen en reserva como acciones en tesorería.
Oculis Holding AG (Nasdaq: OCS; XICE: OCS)는 기존 자본에서 청바지 가치로 각각 CHF 0.01인 2,500,000개의 새로운 보통주를 발행했습니다. 이 주식은 현재 자기주식으로 기록되고 있습니다. 회사의 총 등록 주식 수는 현재 48,943,700으로, 약 4300만 주가 유통되고 있습니다. 이번 발행 이후 자기주식은 회사 등록 주식의 7.2%를 차지합니다.
새로운 주식은 2024년 5월 8일 Leerink Partners와의 판매 계약을 통해 설립된 시장 제공(ATM) 프로그램과 관련하여 발행되었습니다. 이 프로그램에 따라 Oculis는 Leerink Partners를 판매 대리인으로 통해 최대 1억 달러의 보통주를 제공하고 판매할 수 있습니다. 새로 발행된 주식은 ATM 프로그램에서 판매되지 않았으며 자기주식으로 보유되고 있습니다.
Oculis Holding AG (Nasdaq: OCS; XICE: OCS) a émis 2 500 000 nouvelles actions ordinaires enregistrées d'une valeur nominale de CHF 0,01 chacune à partir de son capital existant. Ces actions sont actuellement enregistrées comme actions propres. Le nombre total d'actions enregistrées de l'entreprise s'élève désormais à 48 943 700, avec environ 43 millions d'actions en circulation. Suite à cette émission, les actions propres représentent 7,2 % des actions enregistrées de l'entreprise.
Les nouvelles actions ont été émises dans le cadre d'un programme d'offre sur le marché (ATM) établi via un contrat de vente avec Leerink Partners le 8 mai 2024. Dans le cadre de ce programme, Oculis peut offrir et vendre des actions ordinaires pour une valeur allant jusqu'à 100 millions de dollars par l'intermédiaire de Leerink Partners en tant qu'agent de vente. Les nouvelles actions émises n'ont pas été vendues dans le cadre du programme ATM et sont conservées en réserve en tant qu'actions propres.
Oculis Holding AG (Nasdaq: OCS; XICE: OCS) hat 2.500.000 neue namengegebene Stammaktien mit einem Nennwert von CHF 0,01 aus ihrem bestehenden Kapital emittiert. Diese Aktien sind derzeit als eigene Aktien erfasst. Die Gesamtzahl der registrierten Aktien des Unternehmens beträgt jetzt 48.943.700, wobei etwa 43 Millionen Aktien im Umlauf sind. Nach dieser Emission machen die eigenen Aktien 7,2% der registrierten Aktien des Unternehmens aus.
Die neuen Aktien wurden im Zusammenhang mit einem At-the-Market (ATM) Angebotsprogramm ausgegeben, das am 8. Mai 2024 durch einen Verkaufsvertrag mit Leerink Partners eingerichtet wurde. Im Rahmen dieses Programms kann Oculis Stammaktien im Wert von bis zu 100 Millionen US-Dollar über Leerink Partners als seinen Verkaufsagenten anbieten und verkaufen. Die neu ausgegebenen Aktien wurden im Rahmen des ATM-Programms nicht verkauft und werden als eigene Aktien in Reserve gehalten.
- Established ATM offering program providing access to up to $100 million in potential funding
- Potential future dilution of shareholders through ATM offering program of up to $100 million
ZUG, Switzerland, Jan. 31, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company, has issued registered ordinary shares of the Company, each with a nominal value of CHF 0.01, issued out of existing capital band (Kapitalband), for an aggregate of 2,500,000 ordinary shares of the Company (the "New Shares"), recorded as treasury shares. The number of registered shares issued by the Company as per its Articles of Association is 48,943,700, of which approximately 43 million shares are outstanding. Following the issuance, the number of treasury shares (own shares) held by the Company is
The New Shares were issued in relation to the sales agreement between the Company and Leerink Partners LLC (”Leerink Partners”) entered into on May 8, 2024, with respect to an at-the-market (“ATM”) offering program. Under the ATM offering program, the Company may offer and sell, from time to time at its sole discretion, ordinary shares of the Company having an aggregate offering price of up to
For more details on the ATM offering program, please refer to the Company’s previous press release dated May 17, 2024, and the Company’s SEC filings referenced therein.
For more information, please visit:
http://www.oculis.com
Oculis Contact:
Ms. Sylvia Cheung, CFO
sylvia.cheung@oculis.com
Investor & Media Relations:
LifeSci Advisors
Corey Davis, Ph.D.
cdavis@lifesciadvisors.com
1-212-915-2577
FAQ
How many new shares did Oculis (OCS) issue in January 2025?
What is the total number of outstanding shares for Oculis (OCS) after the January 2025 issuance?
What is the maximum value of shares that can be sold under Oculis' (OCS) ATM program?
What percentage of Oculis' (OCS) registered shares are held as treasury shares after the January 2025 issuance?
